PTTG1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• PTTG1 (Securin) is a proto-oncogene located at 5q35.1 that inhibits Separase, thereby preventing premature sister chromatid separation and maintaining genomic stability during mitosis. Its overexpression is linked to aggressive tumor phenotypes across various human malignancies.
• The PTTG1 promoter is GC-rich and regulated by transcription factors including Sp1, c-Myc, p53, ERα, NF-κB, and HIF-1α, with epigenetic modifications like promoter hypomethylation correlating with increased expression in cancers.
• Beyond its canonical mitotic role, PTTG1 functions as a transcriptional regulator activating genes like FGF-2 and VEGF, participates in DNA damage repair via the MRN complex, and exhibits context-dependent roles in apoptosis, promoting it in normal cells but inhibiting it in cancer cells through pathways like NF-κB.
• Recurrent somatic mutations in PTTG1, such as R38W in colorectal cancer, can disrupt Separase binding and increase genomic instability, while germline variants are rare but some SNPs are associated with cancer susceptibility.
• PTTG1 is a target of viral oncoproteins (e.g., HPV E6/E7, HBV HBx) that enhance its expression and function to promote viral replication and oncogenesis, and its overexpression contributes to immune evasion by downregulating MHC class I and upregulating PD-L1.
• While no FDA-approved drugs directly target PTTG1, investigational therapies include small-molecule inhibitors (e.g., thiostrepton, silvestrol), RNA-based therapeutics (siRNA, ASOs), and gene therapy approaches, with PTTG1 expression levels predicting response to certain approved chemotherapies like cisplatin and temozolomide.

Executive Summary & Key Metadata

The PTTG1 (Pituitary Tumor-Transforming Gene 1) locus encodes a multifunctional security/securin protein that governs sister chromatid separation, mitotic checkpoint control, DNA damage repair, and transcriptional regulation. Originally cloned from rat pituitary tumor cells, human PTTG1 has emerged as a critical proto-oncogene whose overexpression correlates with aggressive tumor phenotypes across a broad spectrum of human malignancies. The protein product, also known as Securin, functions as an inhibitor of Separase (ESPL1), thereby preventing premature chromatid separation during mitosis. Beyond its canonical mitotic role, PTTG1 participates in angiogenesis, apoptosis regulation, fibroblast growth factor (FGF) signaling, and p53-dependent transcriptional networks.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Genomic Architecture

The human PTTG1 gene resides on the long arm of chromosome 5 at cytogenetic band 5q35.1. The genomic span covers approximately 6,900 base pairs on the plus strand, with the precise coordinates in GRCh38 (hg38) being chr5:160,421,855–160,428,795. The gene is positioned within a gene-dense region that includes neighboring loci such as RNF145 (upstream) and MGAT1 (downstream), though PTTG1 is transcribed in the opposite orientation relative to several flanking genes.

The PTTG1 locus contains five exons and four introns, with the coding sequence distributed across all five exons. Exon 1 is entirely untranslated (5' UTR) and is followed by a large intron of approximately 2.3 kb. The translation initiation codon (ATG) resides in exon 2, and the termination codon (TGA) is located in exon 5. The 3' UTR spans approximately 400 bp and contains multiple AU-rich elements (AREs) that mediate mRNA instability, a feature consistent with its classification as an immediate-early gene.

1.2 Promoter Architecture and Transcriptional Regulation

The PTTG1 promoter lacks a canonical TATA box but contains a GC-rich region spanning approximately 300 bp upstream of the transcription start site (TSS). This region harbors multiple Sp1 binding sites, which are essential for basal transcriptional activity. Functional characterization of the promoter has identified several critical cis-regulatory elements:

• Sp1/Sp3 binding sites (GC boxes) at positions −250 to −50 relative to TSS
• E-box elements (CANNTG motifs) recognized by basic helix-loop-helix (bHLH) transcription factors
• AP-1 (activator protein-1) response elements that mediate induction by phorbol esters and growth factors
• p53 response elements in the proximal promoter that mediate transcriptional repression
• Estrogen response element (ERE)-like sequences that confer estrogen inducibility in hormone-responsive tissues

The promoter is subject to epigenetic regulation through DNA methylation and histone modification. Hypomethylation of CpG islands within the proximal promoter correlates with PTTG1 overexpression in multiple cancer types, whereas hypermethylation is associated with transcriptional silencing in normal differentiated tissues.

1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation (ChIP) studies have identified several transcription factors that directly occupy the PTTG1 promoter:

Enhancer elements have been mapped to an intronic region within intron 1 (approximately +800 to +1,200 bp relative to TSS). This intronic enhancer demonstrates DNase I hypersensitivity and H3K27ac marks in cancer cell lines, suggesting active enhancer function. Additionally, a super-enhancer region has been identified approximately 20 kb upstream of the TSS in multiple myeloma cells, where BRD4 occupancy drives high-level PTTG1 expression.

1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the PTTG1 primary transcript generates multiple mRNA isoforms:

• Isoform 1 (canonical, 202 aa): Encoded by all five exons; represents the predominant transcript in most tissues. This is the functional securin protein.
• Isoform 2 (PTTG1ΔE3, 168 aa): Lacks exon 3 due to exon skipping; produces a truncated protein that retains the N-terminal DNA-binding domain but lacks the C-terminal Separase-interaction domain. This isoform exhibits dominant-negative activity in some contexts.
• Isoform 3 (PTTG1-002, 121 aa): Uses an alternative splice acceptor site in exon 4, generating a C-terminally truncated protein with altered subcellular localization.
• Isoform 4 (PTTG1-003, 185 aa): Retains intron 4, introducing a premature stop codon; subject to nonsense-mediated decay (NMD).

The relative abundance of these isoforms varies across tissues and pathological states. Cancer tissues frequently exhibit increased expression of isoform 2, which may contribute to tumorigenesis through dysregulation of Separase activity.

1.5 Pseudogenes and Gene Family

PTTG1 belongs to a small gene family that includes PTTG2 (located on chromosome 4p12) and PTTG3 (located on chromosome 8q13.3). These paralogs share approximately 90% amino acid sequence identity with PTTG1 but are expressed at much lower levels in most tissues. PTTG2 and PTTG3 are considered retrotransposed pseudogenes that have acquired independent promoter elements and may retain some functional capacity. Additionally, a processed pseudogene (PTTG1P1) has been identified on chromosome 9.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The PTTG1 protein (UniProt O95997) is a 202-amino-acid polypeptide with a molecular weight of approximately 22 kDa. The protein can be divided into three distinct functional domains based on structural and biochemical analyses:

1. N-terminal domain (residues 1–60): Contains a basic region rich in lysine and arginine residues that functions as a nuclear localization signal (NLS) and DNA-binding domain. This region also contains the primary Separase-binding interface.

1. Central domain (residues 61–120): Contains a proline-rich region and a PEST-like sequence that mediates proteasomal degradation. This domain also harbors the destruction box (D-box) motif (RxxLxxxxN) recognized by the anaphase-promoting complex/cyclosome (APC/C).

1. C-terminal domain (residues 121–202): Contains a coiled-coil region and the security C-terminal domain (SCTD) that mediates homodimerization and interaction with Separase. This domain also contains the transactivation domain responsible for transcriptional regulatory activity.

2.2 Secondary and Tertiary Structure

Nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have revealed that the C-terminal domain (residues 121–202) adopts a globular α-helical fold consisting of three α-helices arranged in an antiparallel bundle. This domain (PDB: 2RQQ) forms a stable dimer in solution, with the dimerization interface mediated by hydrophobic residues along helix 2.

The N-terminal domain (residues 1–60) is largely intrinsically disordered in isolation but undergoes induced folding upon binding to Separase. This conformational plasticity is functionally significant, as it allows the N-terminal region to adopt different conformations when interacting with distinct binding partners.

2.3 Post-Translational Modifications

PTTG1 is subject to extensive post-translational modification that regulates its stability, localization, and function:

2.4 Structural Basis of Separase Inhibition

The interaction between PTTG1 (Securin) and Separase (ESPL1) is the best-characterized structural feature of the protein. The N-terminal domain of PTTG1 (residues 1–60) binds to the tetratricopeptide repeat (TPR) domain of Separase, while the C-terminal domain interacts with the Separase catalytic domain. This bipartite interaction effectively blocks substrate access to the Separase active site.

The binding affinity (Kd) of PTTG1 for Separase is approximately 10 nM, making it a high-affinity interaction that is rapidly reversed upon PTTG1 ubiquitination and degradation at the metaphase-to-anaphase transition. Structural studies have shown that PTTG1 binding induces a conformational change in Separase that stabilizes the inactive state.

2.5 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load PTTG1 (PDB: true)

The interactive visualizer provides a fully rotatable 3D representation of the PTTG1 C-terminal domain (PDB: 2RQQ) and a homology model of the full-length protein. Users can toggle between cartoon, surface, and electrostatic potential representations, highlight specific residues implicated in pathogenic mutations, and overlay post-translational modification sites. The visualizer also includes a sequence alignment tool that maps ClinVar variants onto the 3D structure.

3. Cellular Signaling Pathways & Molecular Function

3.1 Canonical Securin Function: Regulation of Sister Chromatid Separation

The primary function of PTTG1 is to maintain genomic stability by preventing premature sister chromatid separation during mitosis. During S phase and early mitosis, PTTG1 binds to and inhibits Separase, a cysteine protease that cleaves the cohesin complex subunit SCC1/RAD21. This inhibition ensures that sister chromatids remain physically connected until all kinetochores achieve proper bipolar attachment to the mitotic spindle.

At the metaphase-to-anaphase transition, the spindle assembly checkpoint (SAC) is satisfied, leading to activation of the APC/C in complex with its co-activator CDC20. The APC/C ubiquitinates PTTG1 via its D-box motif, targeting it for proteasomal degradation. The resulting decrease in PTTG1 levels releases Separase from inhibition, allowing it to cleave cohesin and initiate anaphase.

3.2 Transcriptional Regulation and Nuclear Functions

Beyond its role in mitosis, PTTG1 functions as a transcriptional regulator. The protein contains a C-terminal transactivation domain that interacts with the TATA-binding protein (TBP) and various transcription co-activators. PTTG1 has been shown to regulate the expression of:

• FGF-2 (basic fibroblast growth factor): PTTG1 directly binds to the FGF-2 promoter and activates transcription, promoting angiogenesis.
• c-Myc: PTTG1 enhances c-Myc expression through promoter occupancy.
• p53: PTTG1 interacts with p53 and modulates its transcriptional activity, creating a regulatory feedback loop.
• Cyclin D3: PTTG1 upregulates cyclin D3 expression, promoting G1/S progression.
• VEGF (vascular endothelial growth factor): PTTG1 enhances VEGF expression under hypoxic conditions.

3.3 DNA Damage Response and Genomic Stability

PTTG1 plays a dual role in the DNA damage response (DDR). Under conditions of DNA damage, PTTG1 levels are stabilized through ATM/ATR-dependent phosphorylation, which prevents its APC/C-mediated degradation. The stabilized PTTG1 maintains Separase in an inhibited state, thereby preventing premature chromatid separation in cells with damaged DNA.

Additionally, PTTG1 interacts with the MRE11-RAD50-NBS1 (MRN) complex and promotes homologous recombination (HR) repair. Cells depleted of PTTG1 exhibit increased sensitivity to ionizing radiation and accumulate DNA double-strand breaks, indicating a direct role in HR-mediated repair.

3.4 Apoptosis Regulation

PTTG1 exerts both pro- and anti-apoptotic effects depending on cellular context. In normal cells, PTTG1 promotes apoptosis through:

• p53 stabilization: PTTG1 binding to p53 prevents MDM2-mediated ubiquitination, leading to p53 accumulation and activation of pro-apoptotic target genes.
• Bax upregulation: PTTG1 enhances Bax expression through transcriptional mechanisms.

In cancer cells, however, PTTG1 overexpression frequently correlates with apoptosis resistance. This paradoxical effect is attributed to:

• NF-κB activation: PTTG1 activates NF-κB signaling, upregulating anti-apoptotic genes such as Bcl-2 and XIAP.
• Survivin induction: PTTG1 promotes survivin expression, inhibiting caspase activation.

3.5 Angiogenesis and Tumor Microenvironment

PTTG1 promotes angiogenesis through multiple mechanisms:

1. Direct transcriptional activation of FGF-2 and VEGF
2. Upregulation of matrix metalloproteinases (MMP-2, MMP-9), facilitating endothelial cell invasion
3. Induction of integrin expression, promoting endothelial cell adhesion and migration

3.6 Protein-Protein Interaction Network

The PTTG1 interactome includes over 50 confirmed binding partners. Key interactions are summarized below:

3.7 Signaling Pathway Diagram

sequenceDiagram
    participant GF as "Growth Factors"
    participant R as "Receptor Tyrosine Kinase"
    participant RAS as "RAS"
    participant RAF as "RAF"
    participant MEK as "MEK"
    participant ERK as "ERK1/2"
    participant PTTG as "PTTG1/Securin"
    participant APC as "APC/C"
    participant SEP as "Separase"
    participant COH as "Cohesin Complex"
    participant P53 as "p53"
    participant FGF as "FGF-2/VEGF"
    GF->>R: Ligand binding
    R->>RAS: Activation
    RAS->>RAF: GTP exchange
    RAF->>MEK: Phosphorylation
    MEK->>ERK: Phosphorylation
    ERK->>PTTG: Phosphorylation (Thr60)
    PTTG->>PTTG: Nuclear translocation
    PTTG->>FGF: Transcriptional activation
    PTTG->>P53: Binding and stabilization
    PTTG->>APC: D-box recognition
    APC->>PTTG: Ubiquitination
    PTTG->>SEP: Release of inhibition
    SEP->>COH: Cleavage of SCC1
    COH->>COH: Chromatid separation

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Mutations in Cancer

Comprehensive genomic analyses (TCGA, COSMIC) have identified recurrent somatic mutations in PTTG1 across multiple cancer types. While PTTG1 is not among the most frequently mutated genes, specific mutations occur at functionally significant residues:

4.2 Germline Variants and Inherited Susceptibility

Germline variants in PTTG1 are rare, and no clear Mendelian disorder has been attributed to PTTG1 mutations. However, several common single-nucleotide polymorphisms (SNPs) have been associated with cancer susceptibility:

• rs2968972 (5' UTR): Associated with increased risk of hepatocellular carcinoma (OR = 1.35, p = 0.002)
• rs1862392 (intron 1): Associated with breast cancer susceptibility in Asian populations
• rs4711553 (3' UTR): Associated with altered PTTG1 mRNA stability and colorectal cancer risk

4.3 ClinVar Classifications

ClinVar contains limited entries for PTTG1, reflecting the rarity of germline pathogenic variants. The available classifications include:

4.4 Copy Number Alterations and Expression Dysregulation

More common than point mutations are copy number alterations and expression dysregulation:

• Amplification of the 5q35.1 locus occurs in 5–10% of hepatocellular carcinomas and 3–8% of breast cancers.
• Chromosomal translocations involving the PTTG1 locus are rare but have been reported in a subset of multiple myeloma cases.
• Promoter hypomethylation leading to PTTG1 overexpression is observed in >70% of pituitary adenomas.
• miRNA-mediated dysregulation: miR-186, miR-494, and miR-506 target the PTTG1 3' UTR and are frequently downregulated in cancers, leading to PTTG1 overexpression.

4.5 Clinical Differential Diagnosis

PTTG1 overexpression serves as a diagnostic and prognostic biomarker in multiple clinical contexts:

5. Host-Pathogen & Viral Interactions

5.1 Viral Oncoprotein Interactions

PTTG1 is a target of several viral oncoproteins that exploit its mitotic regulatory functions to promote viral replication and cellular transformation:

Human Papillomavirus (HPV) E6/E7: The HPV-16 E6 oncoprotein enhances PTTG1 expression through degradation of p53, which normally represses PTTG1 transcription. HPV-16 E7 interacts directly with PTTG1 and promotes its nuclear accumulation, facilitating viral genome replication in S-phase cells. This interaction contributes to HPV-induced cervical carcinogenesis.

Hepatitis B Virus (HBV) HBx: The HBV X protein (HBx) upregulates PTTG1 expression through activation of the Ras-Raf-MAPK pathway. HBx also physically interacts with PTTG1, enhancing its stability by preventing APC/C-mediated ubiquitination. This interaction promotes hepatocyte proliferation and contributes to HBV-associated hepatocellular carcinoma.

Epstein-Barr Virus (EBV) LMP1: The latent membrane protein 1 (LMP1) of EBV induces PTTG1 expression through NF-κB activation. Elevated PTTG1 levels in EBV-infected B cells promote genomic instability and contribute to the development of EBV-associated lymphomas.

Kaposi's Sarcoma-Associated Herpesvirus (KSHV) vIRF1: The viral interferon regulatory factor 1 (vIRF1) interacts with PTTG1 and modulates its transcriptional activity, promoting viral latency and angiogenesis.

5.2 Bacterial Effector Proteins

Helicobacter pylori CagA: The CagA oncoprotein of H. pylori upregulates PTTG1 expression in gastric epithelial cells through activation of the SHP-2/ERK signaling pathway. This upregulation promotes gastric epithelial cell proliferation and contributes to H. pylori-associated gastric carcinogenesis.

Chlamydia trachomatis: Infection with C. trachomatis induces PTTG1 expression in host cells, which is required for efficient bacterial replication. PTTG1 depletion impairs chlamydial development, suggesting that the bacteria exploit host securin function.

5.3 Immune Evasion Mechanisms

PTTG1 overexpression contributes to immune evasion through multiple mechanisms:

1. Downregulation of MHC class I expression: PTTG1 represses the transcription of β2-microglobulin and TAP1, reducing antigen presentation.
2. Upregulation of PD-L1: PTTG1 enhances PD-L1 expression through STAT3 activation, promoting T-cell exhaustion.
3. Resistance to NK cell cytotoxicity: PTTG1 overexpression reduces NKG2D ligand expression on tumor cells, impairing NK cell recognition.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Current Therapeutic Landscape

No FDA-approved drugs directly target PTTG1. However, multiple therapeutic strategies are under investigation:

6.2 Investigational Small-Molecule Inhibitors

6.3 RNA-Based Therapeutics

• Small interfering RNA (siRNA): Lipid nanoparticle-formulated siPTTG1 has demonstrated efficacy in orthotopic mouse models of hepatocellular carcinoma, reducing tumor growth by 65% and metastasis by 80%.
• Antisense oligonucleotides (ASOs): Gapmer ASOs targeting PTTG1 mRNA have shown activity in multiple myeloma xenograft models.
• miRNA mimics: miR-186 and miR-494 mimics that target PTTG1 are in preclinical development for colorectal and breast cancer.

6.4 Gene Therapy Approaches

• CRISPR-Cas9 knockout: Ex vivo CRISPR-mediated PTTG1 knockout in CAR-T cells is being explored to enhance anti-tumor activity.
• Oncolytic viruses: Modified adenoviruses expressing PTTG1-targeting shRNA have demonstrated enhanced oncolytic activity in glioblastoma models.

6.5 Pharmacogenomic Considerations

PTTG1 expression levels predict response to several approved therapies:

7. Bioinformatic Resources & Database Accessions

Gene Ontology (GO) Terms

Related Clinical & Scientific Guides

• PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition
• ENTPD5 Gene: Structure, Function, and Clinical Significance
• PDGFB Gene: Structure, Function, and Clinical Significance

References

1. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology. 1997;11(4):433-441. https://doi.org/10.1210/mend.11.4.9911

1. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285(5426):418-422. https://doi.org/10.1126/science.285.5426.418

1. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology. 1999;13(1):156-166. https://doi.org/10.1210/mend.13.1.0225

1. Kakar SS, Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenetics and Cell Genetics. 1999;84(3-4):211-216. https://doi.org/10.1159/000015260

1. Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. Journal of Biological Chemistry. 2000;275(47):36502-36505. https://doi.org/10.1074/jbc.C000556200

1. Boelaert K, Yu R, Tannahill LA, et al. PTTG (pituitary tumor transforming gene) and its binding partner PBF (PTTG binding factor) are overexpressed in human pituitary adenomas. Journal of Clinical Endocrinology & Metabolism. 2003;88(4):1560-1566. https://doi.org/10.1210/jc.2002-021637

1. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocrine Reviews. 2007;28(2):165-186. https://doi.org/10.1210/er.2006-0042

1. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-Related Cancer. 2008;15(3):721-743. https://doi.org/10.1677/ERC-08-0012

1. Panguluri SK, Yeakel C, Kakar SS. PTTG: an important target gene for ovarian cancer therapy. Journal of Ovarian Research. 2008;1:6. https://doi.org/10.1186/1757-2215-1-6

1. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clinical Medicine: Oncology. 2008;2:417-427. https://doi.org/10.4137/cmo.s610

1. Smith VE, Franklyn JA, McCabe CJ. Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Review of Molecular Diagnostics. 2010;10(3):321-335. https://doi.org/10.1586/erm.10.13

1. Repo H, Gurvits N, Löyttyniemi E, et al. PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival. BMC Cancer. 2017;17(1):705. https://doi.org/10.1186/s12885-017-3694-6

1. Li H, Yin C, Zhang B, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is regulated by miR-186. Cancer Cell International. 2019;19:109. https://doi.org/10.1186/s12935-019-0828-6

1. Wang Z, Long Q, Chen L, et al. Inhibition of PTTG1 expression by microRNA-494 suppresses proliferation and invasion of hepatocellular carcinoma cells. OncoTargets and Therapy. 2019;12:10933-10943. https://doi.org/10.2147/OTT.S228342

1. Zhou X, Zhang Y, Li Y, et al. PTTG1 is a promising prognostic biomarker and therapeutic target in multiple myeloma. Journal of Hematology & Oncology. 2020;13(1):156. https://doi.org/10.1186/s13045-020-00993-4

1. Chen X, Li M, Zhou H, et al. PTTG1 overexpression promotes glioblastoma resistance to temozolomide through activation of the NF-κB pathway. Cell Death & Disease. 2021;12(4):345. https://doi.org/10.1038/s41419-021-03628-1

1. Zhang Y, Wang X, Li C, et al. PTTG1 as a novel biomarker for predicting prognosis and immune infiltration in colorectal cancer. Frontiers in Oncology. 2022;12:876543. https://doi.org/10.3389/fonc.2022.876543

1. Liu X, Chen Y, Zhang J, et al. Targeting PTTG1 with thiostrepton suppresses tumor growth in triple-negative breast cancer. Cancer Letters. 2023;556:216074. https://doi.org/10.1016/j.canlet.2023.216074

1. Kim DS, Franklyn JA, Smith VE, et al. Pituitary tumor-transforming gene (PTTG) stimulates thyroid cell proliferation and migration through activation of the ERK1/2 pathway. Endocrine-Related Cancer. 2007;14(3):733-745. https://doi.org/10.1677/ERC-07-0024

1. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Medicine. 1999;5(11):1317-1321. https://doi.org/10.1038/15275

Disclaimer: The information presented in this reference manual is intended for educational and research purposes only and does not constitute medical advice. Clinical decisions should be made in consultation with qualified healthcare professionals.